IFNB1 and relapsing-remitting multiple sclerosis: To this end, both the E. coli-derived IFN-β variant named IFN-β−1b and CHO-produced IFN-β marketed as IFN-β−1a have been implemented in the treatment of relapsing-remitting multiple sclerosis.